Annular elastolytic giant cell granuloma after COVID-19 vaccination
https://doi.org/10.4081/dr.2023.9811
HTML: 6
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
The pandemic of SARS-CoV-2 during the first years of the 2020s led to a great commitment to develop effective vaccines. Despite the good safety and tolerability profile, vaccines may trigger a broad spectrum of cutaneous side effects. Granulomatous dermatitis has been rarely reported after SARS-CoV-2 mRNA vaccines, but no cases of annular elastolytic giant cell granuloma have been described. Moreover, in our case, it was also associated with a central area of mid-dermal elastolysis, confirming the strong association between these two diseases already reported in the literature. The observation of occasional eosinophils within the infiltrate and the presentation of the cutaneous eruption a few days after the administration of the second dose of the Pfizer/BioNTech (BNT162b2) vaccine are highly suggestive of a drug-related eruption. To our knowledge, this is the first report in the literature of an annular elastolytic giant cell granuloma as an adverse effect of the SARS-CoV-2 vaccination.
Teo SP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J Pharm Pract 2022;35:947-51.
Wallace M, Woodworth KR, Gargano JW, et al. The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years - United States, May 2021. MMWR Morb Mortal Wkly Rep 2021;70:749-52.
Wallace M, Moulia D, Blain AE, et al. The advisory committee on immunization practices’ recommendation for use of Moderna COVID-19 vaccine in adults aged ≥18 years and considerations for extended intervals for administration of primary series doses of mRNA COVID-19 vaccines - United States, February 2022. MMWR Morb Mortal Wkly Rep 2022;71:416-21.
Niebel D, Novak N, Wilhelmi J, et al. Cutaneous adverse reactions to COVID-19 vaccines: insights from an immuno-dermatological perspective. Vaccines 2021;9:944.
Lamberti A, Lora V, Graceffa D, et al. Nail psoriasis: a rare mRNA COVID-19 vaccine reaction. J Eur Acad Dermatol Venereol 2022;36:e745-6.
Nguyen TH, Gabros S, Friefeld S, et al. Generalized granuloma annulare after COVID-19 vaccination. JAAD Case Rep 2022;25:18-21.
Qian YT, Liu JW, Liu W, et al. A retrospective study of 105 patients with elastolytic giant cell granuloma and a proposal for a new clinical classification. Acta Derm Venereol 2022;102:adv00684.
Müller FB, Groth W. Annular elastolytic giant cell granuloma: a prodromal stage of mid-dermal elastolysis? Br J Dermatol 2007;156:1377-9.
Nunez-Castilla J, Stebliankin V, Baral P, et al. Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins. Viruses 2022;14:1415.
Cota C, Latini A, Lora V, Cerroni L. Mid-dermal elastolysis as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected patient. J Am Acad Dermatol 2014;71:e134-5.
Ernst M, Giubellino A. Histopathologic features of maculopapular drug eruption. Dermatopathology 2022;9:111-21.
Magro C, Crowson AN, Franks L, et al. The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin. Clin Dermatol 2021;39:966-84.
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
